BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 25588160)

  • 1. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
    Deng M; Wang J; Chen Y; Zhang L; Liu D
    Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
    Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
    Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
    Liu ZY; He KW; Song XG; Wang XZ; Zhuo PY; Wang XW; Ma QH; Huo ZJ; Yu ZY
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):417-24. PubMed ID: 27346398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
    Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
    Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways].
    Cheng H; Zhang X; Su JJ; Li QL
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1666-9. PubMed ID: 25095381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
    Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
    Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J
    Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
    Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
    J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.